Preliminary Study for Selective Detection of the CD8+ Myelin Specific T Cell in the Blood of Multiple Sclerosis Patients

Inclusion Criteria: Group 1: HLA-A2 patients whose Multiple Sclerosis has just been diagnosed * 18 year old and older patients, * HLA-A2 Patients with Multiple Sclerosis or clinically isolated syndrome at high risk of being affected by Multiple Sclerosis (criteria of spatial scattering according to the 2010 or 2005 McDonald's criteria) * Patients without treatment or treated with immunomodulating therapy * Patients affiliated to health insurance coverage * Information and comprehensive agreement signed by the patient and the investigator Group 2: HLA-A2 patients hospitalized in the neurology department who are not affected with a neuroimmunological disorder * 18 year old and older patients, * HLA-A2 patients hospitalized in the neurology department * Patient not affected by Multiple Sclerosis or a related inflammatory disorder * Affiliated or profitable subject of a national insurance scheme * Patients affiliated to health insurance coverage * Information and comprehensive agreement signed by the patient and the investigator Group 3: HLA-A2 Multiple Sclerosis patients treated by Natalizumab therapy * 18 year old and older patients, * HLA-A2 patients with relapsing remitting (RR) MS fulfilling McDonald 2005 or 2010 Multiple Sclerosis diagnostic criteria * Patients treated by Natalizumab therapy for at least 3 months * Patients affiliated to health insurance coverage * Information and comprehensive agreement signed by the patient and the investigator Exclusion Criteria: Group 1 and 3: * Patients undergoing immunosuppressive therapy at present or in the past except Natalizumab * Pregnant women Group 2: * Patients undergoing immunosuppressive therapy at present or in the past * Patients affected by Multiple Sclerosis or a related disorder * Pregnant women